| pubmed-article:9200473 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9200473 | lifeskim:mentions | umls-concept:C0085424 | lld:lifeskim |
| pubmed-article:9200473 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:9200473 | lifeskim:mentions | umls-concept:C0699885 | lld:lifeskim |
| pubmed-article:9200473 | lifeskim:mentions | umls-concept:C0006556 | lld:lifeskim |
| pubmed-article:9200473 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:9200473 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:9200473 | lifeskim:mentions | umls-concept:C0206243 | lld:lifeskim |
| pubmed-article:9200473 | lifeskim:mentions | umls-concept:C1555370 | lld:lifeskim |
| pubmed-article:9200473 | lifeskim:mentions | umls-concept:C1711351 | lld:lifeskim |
| pubmed-article:9200473 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:9200473 | lifeskim:mentions | umls-concept:C1510800 | lld:lifeskim |
| pubmed-article:9200473 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9200473 | pubmed:dateCreated | 1997-7-14 | lld:pubmed |
| pubmed-article:9200473 | pubmed:abstractText | IL-12 is a heterodimeric immunoregulatory cytokine composed of covalently linked p40 and p35 subunits and exhibits antitumor activity in a variety of laboratory models. The efficacy of systemically administered cytokines for cancer therapy is often limited by toxicity. The gene therapy approach provides a mechanism to achieve temporary and high local concentrations of cytokines within a tumor with less risk of systemic toxicity. We constructed replication-defective adenoviruses containing the murine IL-12 p40 subunit (Ad.mp40) or a bicistronic vector containing cDNAs for the p40 and p35 subunits (Ad.mIL-12). Murine MB49 bladder cancer cells infected with Ad.mIL-12 secrete high concentrations of biologically active IL-12, while those infected with Ad.mp40 produce the p40 homodimer. Tumors injected with Ad.mIL-12 show rapid increases in IL-12 and IFN-gamma expression over 2 to 5 days and a return to baseline by 7 to 14 days. Injection of tumors with Ad.mIL-12 (1 x 10(9) plaque-forming units) results in a complete tumor regression in all mice, while those treated with control adenovirus succumb to their tumor. Efficacy is reduced when studies are performed in mice depleted of CD4+ and CD8+ cells or in nude mice. Mice cured of their tumor by Ad.mIL-12 demonstrate specific protective immunity upon rechallenge. Ad.mp40 does not exhibit antitumor activity and may antagonize the activity of rIL-12 or Ad.mIL-12. In summary, gene therapy strategies for cancer using adenoviral vectors containing IL-12 are highly effective with no significant toxicity in mice. | lld:pubmed |
| pubmed-article:9200473 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9200473 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9200473 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9200473 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9200473 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9200473 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9200473 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9200473 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9200473 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9200473 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:9200473 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:9200473 | pubmed:author | pubmed-author:BlochBB | lld:pubmed |
| pubmed-article:9200473 | pubmed:author | pubmed-author:ChenLL | lld:pubmed |
| pubmed-article:9200473 | pubmed:author | pubmed-author:ClintonS KSK | lld:pubmed |
| pubmed-article:9200473 | pubmed:author | pubmed-author:ChenDD | lld:pubmed |
| pubmed-article:9200473 | pubmed:author | pubmed-author:KufeD WDW | lld:pubmed |
| pubmed-article:9200473 | pubmed:author | pubmed-author:O'DonnellMM | lld:pubmed |
| pubmed-article:9200473 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9200473 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9200473 | pubmed:volume | 159 | lld:pubmed |
| pubmed-article:9200473 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9200473 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9200473 | pubmed:pagination | 351-9 | lld:pubmed |
| pubmed-article:9200473 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:meshHeading | pubmed-meshheading:9200473-... | lld:pubmed |
| pubmed-article:9200473 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9200473 | pubmed:articleTitle | Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. | lld:pubmed |
| pubmed-article:9200473 | pubmed:affiliation | Dana-Farber Cancer Institute, Department of Urology, Harvard Medical School, Boston, MA 02115, USA. | lld:pubmed |
| pubmed-article:9200473 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9200473 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9200473 | lld:pubmed |
